Literature DB >> 32443148

Kinetics of Plasma HIV Rebound in the Era of Modern Antiretroviral Therapy.

Michael C Sneller1, Erin D Huiting1, Katherine E Clarridge1, Catherine Seamon2, Jana Blazkova1, Jesse S Justement1, Victoria Shi1, Emily J Whitehead1, Rachel F Schneck1, Michael Proschan3, Susan Moir1, Anthony S Fauci1, Tae-Wook Chun1.   

Abstract

Historical data regarding time to viral rebound following analytical treatment interruption (ATI) have been used to determine therapeutic efficacy in HIV cure trials; however, such data were collected from studies conducted a decade or more ago and included participants receiving older antiretroviral therapy (ART) regimens with infrequent virologic monitoring. We conducted a study of 22 HIV-infected participants receiving modern ART to determine the kinetics of plasma viral rebound following ATI. Our data suggest that modern ART does not alter kinetics of viral rebound when compared to previous regimens and that immunologic interventions may be necessary to achieve ART-free virologic remission. Clinical Trials Registration ClinicaTrials.gov identifier: NCT03225118. Published by Oxford University Press for the Infectious Diseases Society of America 2020.

Entities:  

Keywords:  analytical treatment interruption; antiretroviral therapy; human immunodeficiency virus

Mesh：

Substances：

Year:  2020        PMID： 32443148      PMCID： PMC7751567          DOI： 10.1093/infdis/jiaa270

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  15 in total

1.  The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.

Authors:  Golnaz Namazi; Jesse M Fajnzylber; Evgenia Aga; Ronald J Bosch; Edward P Acosta; Radwa Sharaf; Wendy Hartogensis; Jeffrey M Jacobson; Elizabeth Connick; Paul Volberding; Daniel Skiest; David Margolis; Michael C Sneller; Susan J Little; Sara Gianella; Davey M Smith; Daniel R Kuritzkes; Roy M Gulick; John W Mellors; Vikram Mehraj; Rajesh T Gandhi; Ronald Mitsuyasu; Robert T Schooley; Keith Henry; Pablo Tebas; Steven G Deeks; Tae-Wook Chun; Ann C Collier; Jean-Pierre Routy; Frederick M Hecht; Bruce D Walker; Jonathan Z Li
Journal:  J Infect Dis       Date:  2018-11-05       Impact factor: 5.226

2.  HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression.

Authors:  R T Davey; N Bhat; C Yoder; T W Chun; J A Metcalf; R Dewar; V Natarajan; R A Lempicki; J W Adelsberger; K D Miller; J A Kovacs; M A Polis; R E Walker; J Falloon; H Masur; D Gee; M Baseler; D S Dimitrov; A S Fauci; H C Lane
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

Review 3.  Assays to Measure Latency, Reservoirs, and Reactivation.

Authors:  Janet D Siliciano; Robert F Siliciano
Journal:  Curr Top Microbiol Immunol       Date:  2018       Impact factor: 4.291

4.  Decay characteristics of HIV-1-infected compartments during combination therapy.

Authors:  A S Perelson; P Essunger; Y Cao; M Vesanen; A Hurley; K Saksela; M Markowitz; D D Ho
Journal:  Nature       Date:  1997-05-08       Impact factor: 49.962

Review 5.  The end of AIDS: HIV infection as a chronic disease.

Authors:  Steven G Deeks; Sharon R Lewin; Diane V Havlir
Journal:  Lancet       Date:  2013-10-23       Impact factor: 79.321

6.  The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.

Authors:  Robert J Johnston; Laetitia Comps-Agrar; Jason Hackney; Xin Yu; Mahrukh Huseni; Yagai Yang; Summer Park; Vincent Javinal; Henry Chiu; Bryan Irving; Dan L Eaton; Jane L Grogan
Journal:  Cancer Cell       Date:  2014-11-26       Impact factor: 31.743

7.  The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption.

Authors:  Jonathan Z Li; Behzad Etemad; Hayat Ahmed; Evgenia Aga; Ronald J Bosch; John W Mellors; Daniel R Kuritzkes; Michael M Lederman; Michael Para; Rajesh T Gandhi
Journal:  AIDS       Date:  2016-01-28       Impact factor: 4.177

8.  Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals.

Authors:  Katherine E Clarridge; Jana Blazkova; Kevin Einkauf; Mary Petrone; Eric W Refsland; J Shawn Justement; Victoria Shi; Erin D Huiting; Catherine A Seamon; Guinevere Q Lee; Xu G Yu; Susan Moir; Michael C Sneller; Mathias Lichterfeld; Tae-Wook Chun
Journal:  PLoS Pathog       Date:  2018-01-11       Impact factor: 6.823

Review 9.  CD8+ T cells in HIV control, cure and prevention.

Authors:  David R Collins; Gaurav D Gaiha; Bruce D Walker
Journal:  Nat Rev Immunol       Date:  2020-02-12       Impact factor: 53.106

10.  Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection.

Authors:  Donn J Colby; Lydie Trautmann; Suteeraporn Pinyakorn; Louise Leyre; Amélie Pagliuzza; Eugène Kroon; Morgane Rolland; Hiroshi Takata; Supranee Buranapraditkun; Jintana Intasan; Nitiya Chomchey; Roshell Muir; Elias K Haddad; Sodsai Tovanabutra; Sasiwimol Ubolyam; Diane L Bolton; Brandie A Fullmer; Robert J Gorelick; Lawrence Fox; Trevor A Crowell; Rapee Trichavaroj; Robert O'Connell; Nicolas Chomont; Jerome H Kim; Nelson L Michael; Merlin L Robb; Nittaya Phanuphak; Jintanat Ananworanich
Journal:  Nat Med       Date:  2018-06-11       Impact factor: 53.440
View more
  7 in total

Review 1.  Viral and Host Biomarkers of HIV Remission Post Treatment Interruption.

Authors:  Leila B Giron; Mohamed Abdel-Mohsen
Journal:  Curr HIV/AIDS Rep       Date:  2022-04-19       Impact factor: 5.071

2.  Transformation of dolutegravir into an ultra-long-acting parenteral prodrug formulation.

Authors:  Suyash Deodhar; Brady Sillman; Aditya N Bade; Sean N Avedissian; Anthony T Podany; JoEllyn M McMillan; Nagsen Gautam; Brandon Hanson; Bhagya L Dyavar Shetty; Adam Szlachetka; Morgan Johnston; Michellie Thurman; Daniel J Munt; Alekha K Dash; Milica Markovic; Arik Dahan; Yazen Alnouti; Alborz Yazdi; Bhavesh D Kevadiya; Siddappa N Byrareddy; Samuel M Cohen; Benson Edagwa; Howard E Gendelman
Journal:  Nat Commun       Date:  2022-06-09       Impact factor: 17.694

3.  Clinical validation of a quantitative HIV-1 DNA droplet digital PCR assay: Applications for detecting occult HIV-1 infection and monitoring cell-associated HIV-1 dynamics across different subtypes in HIV-1 prevention and cure trials.

Authors:  Laura Powell; Adit Dhummakupt; Lilly Siems; Dolly Singh; Yann Le Duff; Priyanka Uprety; Cheryl Jennings; Joseph Szewczyk; Ya Chen; Eleni Nastouli; Deborah Persaud
Journal:  J Clin Virol       Date:  2021-04-14       Impact factor: 14.481

4.  Safety, Immune, and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical Trial.

Authors:  Emmanouil Papasavvas; Livio Azzoni; Amélie Pagliuzza; Mohamed Abdel-Mohsen; Brian N Ross; Matthew Fair; Bonnie J Howell; Daria J Hazuda; Nicolas Chomont; Qingsheng Li; Karam Mounzer; Jay R Kostman; Pablo Tebas; Luis J Montaner
Journal:  AIDS Res Hum Retroviruses       Date:  2021-01-29       Impact factor: 1.723

5.  Persistence of Unintegrated HIV DNA Associates With Ongoing NK Cell Activation and CD34+DNAM-1brightCXCR4+ Precursor Turnover in Vertically Infected Patients Despite Successful Antiretroviral Treatment.

Authors:  Lucia Taramasso; Federica Bozzano; Anna Casabianca; Chiara Orlandi; Francesca Bovis; Sara Mora; Mauro Giacomini; Lorenzo Moretta; Mauro Magnani; Antonio Di Biagio; Andrea De Maria
Journal:  Front Immunol       Date:  2022-04-26       Impact factor: 8.786

Review 6.  Analytical Treatment Interruption in HIV Trials: Statistical and Study Design Considerations.

Authors:  Lu Zheng; Camlin Tierney; Ronald J Bosch
Journal:  Curr HIV/AIDS Rep       Date:  2021-07-02       Impact factor: 5.495

7.  Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies.

Authors:  Jonathan Z Li; Evgenia Aga; Ronald J Bosch; Mark Pilkinton; Eugène Kroon; Lynsay MacLaren; Michael Keefer; Lawrence Fox; Liz Barr; Edward Acosta; Jintanat Ananworanich; Robert Coombs; John W Mellors; Alan L Landay; Bernard Macatangay; Steven Deeks; Rajesh T Gandhi; Davey M Smith
Journal:  Clin Infect Dis       Date:  2022-03-09       Impact factor: 20.999
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.